profit from every $100 of sales.
$0$100
NovaBay Pharmaceuticals
We have no price for NovaBay Pharmaceuticals since 8 June 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$1.16+3.57% today
-90.3% since Oct 8, 25
1-year low $1.121-year high $106.40
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
NovaBay Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| NovaBay Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads NovaBay Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- 0.2×
- –
- –
- –
- -21.5%
- -56.6%
- 396.0%
Profitability
- -3.5%
- -213.9%
- 21,217.7%
- -210.5%
- -3.0%
- -133.1%
- 1,715.1%
- 290.7%
- -3.0%
- –
Growth
- –
- –
- −62.5%
- –
- +146.3%
Financial health
- 3.4×
- 0.00
- 0.4%
- -18.8×
- 5.29
- 5.29
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 30%of 958
Bottom 3%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 1, 2026 | 21.23 | -1.00 | +2,223.0% |
| Mar 30, 2026 | -4.69 | -1.00 | −369.0% |
| Nov 7, 2025 | -0.23 | -0.21 | −9.5% |
| Aug 14, 2025 | -0.34 | -0.21 | −61.9% |
| May 15, 2025 | -0.61 | -0.24 | −154.2% |
| Apr 1, 2025 | -33.22 | -0.24 | −13,741.7% |
| Nov 7, 2024 | -0.60 | -0.28 | −114.3% |
| Aug 13, 2024 | -1.37 | -1.23 | −11.4% |
396.0%of the share price, paid each year
On $1,000 invested$3960a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
0.9% of its profit
Room to growStretchedMore than it earns: -57.1%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
75Pass
Philip Fisher
27No pass
Peter Lynch
2No pass
Joel Greenblatt
2No pass
Charlie Munger
16No pass
Terry Smith
16No pass
Questions about NovaBay Pharmaceuticals
Is NovaBay Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the NovaBay Pharmaceuticals AI analysis
What does NovaBay Pharmaceuticals do?
NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that specializes in developing and globally distributing products for eyecare and dermatology. It is in Biotechnology.
Does NovaBay Pharmaceuticals pay a dividend?
Yes. At today's price the dividend is 396.0% a year, about 1% of its yearly profit.
Is NovaBay Pharmaceuticals stock halal?
Yes. NovaBay Pharmaceuticals passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
Who are NovaBay Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with NovaBay Pharmaceuticals's.
Prices: daily closes to Jun 8, 2026. Fundamentals: company reports via invest-like data.